French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) is expected to launch in the United States in Q4 2026.

Swiss/Icelandic ophthalmology biotech listed on Nasdaq. Following the failure of the DIAMOND-1 and DIAMOND-2 pivotal trials (OCS-01 in diabetic macular oedema, announced 29 May 2026), the thesis is being recentred on two assets: licaminlimab (OCS-02) in severe dry eye disease and privosegtor (OCS-05) in optic neuropathy neuroprotection.